Evidence map›Paper›PMID 27593345›Full record

ArticleCancer cell2016

An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression.

Mansoor Ahmed, Joseph L Sottnik, Garrett M Dancik, Divya Sahu, Donna E Hansel, Dan Theodorescu, Martin A Schwartz

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 78 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Spatial multi-omics reveals the potential involvement of SPP1Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. The Novel Role of GDI2: A Mini-Review.Annals of medicine and medical research · 2024
    Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Mansoor AhmedDepartment of Internal Medicine (Cardiology), Yale Cardiovascular Research Center, Yale University, New Haven, CT 06520, USA. Electronic address: mansoornccs@gmail.com.
Joseph L SottnikDepartment of Surgery, University of Colorado, Aurora, CO 80045, USA.
Garrett M DancikMathematics and Computer Science Department, Eastern Connecticut State University, Willimantic, CT 06226, USA.
Divya SahuDepartment of Pathology, University of California, San Diego, La Jolla, CA 92093, USA.
Donna E HanselDepartment of Pathology, University of California, San Diego, La Jolla, CA 92093, USA.
Dan TheodorescuDepartment of Surgery, University of Colorado, Aurora, CO 80045, USA; Department of Pharmacology, University of Colorado, Aurora, CO 80045, USA; University of Colorado Comprehensive Cancer Center, Aurora, CO 80045, USA. Electronic address: dan.theodorescu@ucdenver.edu.
Martin A SchwartzDepartment of Internal Medicine (Cardiology), Yale Cardiovascular Research Center, Yale University, New Haven, CT 06520, USA; Departments of Cell Biology and Biomedical Engineering, Yale University, New Haven, CT 06520, USA. Electronic address: martin.schwartz@yale.edu.
University of California, San Diego · USUniversity of Colorado Denver · USYale University · USEastern Connecticut State University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Understanding the RhoGDI2 metastasis suppressor geneR01CA143971 · NCI · UNIVERSITY OF COLORADO DENVER · PI THEODORESCU, DAN · 2010 to 2020
$4.4M
NCATS NIH HHS UL1 TR001863NCI NIH HHS R01 CA143971
6 · The paper itself

Abstract

RhoGDI2 specifically suppresses bladder cancer metastasis but not primary tumor growth, which involves tumor-associated macrophages. We report that macrophage-secreted osteopontin binds to CD44s on the tumor cells and promotes invasion and clonal growth. These effects are RhoGDI2-sensitive and require CD44s binding to the Rac GEF TIAM1. Osteopontin expression correlates with tumor aggressiveness and poor clinical outcome in patients. Inhibiting this pathway potently blocked lung and lymph node metastasis; however, primary tumors and established metastasis were less sensitive. Osteopontin-CD44s-TIAM1 promotes clonal growth in vitro but not at high cell density. These data identify osteopontin-CD44-TIAM1-Rac1 axis as a RhoGDI2-sensitive pathway and potential therapeutic target in bladder cancer metastasis. They also elucidate the mechanism behind RhoGDI2 specificity for metastasis over established tumors.

Indexed as

AnimalsHumansHyaluronan ReceptorsLung NeoplasmsMiceMice, NudeNeoplasm MetastasisOsteopontinrho Guanine Nucleotide Dissociation Inhibitor betaUrinary Bladder NeoplasmsHyaluronan ReceptorsOsteopontinrho Guanine Nucleotide Dissociation Inhibitor beta

Identifiers

PMID27593345
PMCPMC5154333
OpenAlexW2518448021

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.